bioMerieux (BMXMF) Stock Price, News & Analysis

Company Overview

bioMérieux is a France-based healthcare company specializing in in vitro diagnostics. The company develops, manufactures and markets diagnostic systems, reagents and software used to detect infectious diseases, support antimicrobial therapy decisions and assist with disease management.

Its product portfolio includes solutions for microbiology, molecular biology, immunoassays and syndromic testing. bioMérieux’s systems are used by hospitals, clinical laboratories and healthcare providers, while its industrial applications serve the food, pharmaceutical and cosmetics industries by helping customers monitor contamination, quality and safety.

Founded in 1963 by Alain Mérieux, bioMérieux traces its heritage to the Mérieux family’s work in medical diagnostics. Headquartered near Lyon, France, the company serves customers internationally through operations and commercial networks across major global markets. Alexandre Mérieux serves as chairman of the company, which remains closely associated with the Mérieux family.

Key Stats

• Today's Range: $87.75 to $87.79
• 50-Day Range: $78.99 to $88.67
• 52-Week Range: $77.00 to $132.52
• Volume: 120 shs
• Average Volume: 184 shs
• Market Capitalization: $10.39 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

bioMerieux Stock Analysis - MarketRank™

bioMerieux scored higher than 26% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Reduce

Consensus Rating

bioMerieux has received a consensus rating of Reduce. The company's average rating score is 1.83, and is based on no strong buy ratings, no buy ratings, 5 hold ratings, and 1 sell rating.

Amount of Analyst Coverage

bioMerieux has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: 7.62%

Earnings Growth

Earnings for bioMerieux are expected to grow by 7.62% in the coming year, from $5.12 to $5.51 per share.

Price to Book Value per Share Ratio

bioMerieux has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.11% of the float of bioMerieux has been sold short.

Short Interest Ratio / Days to Cover

bioMerieux has a short interest ratio ("days to cover") of 999.99, which indicates bearish sentiment.

Change versus previous month

Short interest in bioMerieux has recently decreased by 0.31%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

bioMerieux does not currently pay a dividend.

Dividend Growth

bioMerieux does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.67

News Sentiment

bioMerieux has a news sentiment score of 0.67. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for bioMerieux this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, bioMerieux insiders have not sold or bought any company stock.

Percentage Held by Institutions

bioMerieux has minimal institutional ownership at this time.

Company Calendar

• Today: 10/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:BMXMF
• CIK: N/A
• Web: www.biomerieux.com
• Phone: 33-04-78-87-20-00
• Fax: 33-04-78-87-20-90
• Employees: 14,600
• Year Founded: 1963

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $4.60 billion
• Price / Sales: 2.26
• Cash Flow: $9.78 per share
• Price / Cash Flow: 8.97
• Book Value: $39.25 per share
• Price / Book: 2.24

Miscellaneous

• Outstanding Shares: 118,360,000
• Free Float: N/A
• Market Cap: $10.39 billion
• Optionable: Not Optionable
• Beta: 0.75